Total Payments
$1.3M
2024 Payments
$213,005
Companies
50
Transactions
1,088
Medicare Patients
3,482
Medicare Billing
$1.8M
Payment Breakdown by Category
Other$878,680 (67.9%)
Consulting$244,322 (18.9%)
Travel$141,658 (10.9%)
Food & Beverage$28,739 (2.2%)
Research$478.43 (0.0%)
Education$384.23 (0.0%)
Gifts$245.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $866,414 | 259 | 66.9% |
| Consulting Fee | $244,322 | 87 | 18.9% |
| Travel and Lodging | $141,658 | 306 | 10.9% |
| Food and Beverage | $28,739 | 408 | 2.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,946 | 5 | 0.6% |
| Honoraria | $4,321 | 9 | 0.3% |
| Unspecified | $478.43 | 3 | 0.0% |
| Education | $384.23 | 10 | 0.0% |
| Gift | $245.27 | 1 | 0.0% |
Payments by Type
General
$1.3M
1,085 transactions
Research
$478.43
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $490,818 | 366 | $0 (2024) |
| GlaxoSmithKline, LLC. | $273,765 | 143 | $0 (2024) |
| TESARO, Inc. | $92,593 | 119 | $0 (2019) |
| Genmab U.S., Inc. | $60,356 | 37 | $0 (2024) |
| Clovis Oncology, Inc. | $60,133 | 72 | $0 (2022) |
| Eisai Inc. | $59,792 | 44 | $0 (2024) |
| Seagen Inc. | $53,015 | 34 | $0 (2023) |
| Merck Sharp & Dohme LLC | $40,125 | 48 | $0 (2024) |
| Genentech USA, Inc. | $36,129 | 41 | $0 (2019) |
| ABBVIE INC. | $30,205 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $213,005 | 137 | GlaxoSmithKline, LLC. ($105,604) |
| 2023 | $249,474 | 157 | GlaxoSmithKline, LLC. ($101,079) |
| 2022 | $178,671 | 119 | AstraZeneca Pharmaceuticals LP ($81,249) |
| 2021 | $100,132 | 70 | AstraZeneca Pharmaceuticals LP ($46,448) |
| 2020 | $102,430 | 75 | AstraZeneca Pharmaceuticals LP ($63,107) |
| 2019 | $287,402 | 290 | AstraZeneca Pharmaceuticals LP ($159,273) |
| 2018 | $95,917 | 124 | AstraZeneca Pharmaceuticals LP ($36,540) |
| 2017 | $67,477 | 116 | TESARO, Inc. ($28,827) |
All Payment Transactions
1,088 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 12/16/2024 | Pacira Pharmaceuticals Incorporated | Iovera (Device) | Food and Beverage | In-kind items and services | $128.04 | General |
| Category: Pain Management | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | In-kind items and services | $4,000.00 | General |
| Category: Oncology | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Travel and Lodging | Cash or cash equivalent | $289.37 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| 11/21/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,654.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $512.40 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $382.20 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $139.89 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Travel and Lodging | In-kind items and services | $324.00 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Eisai Inc. | Lenvima (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $815.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $654.14 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $238.68 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $124.77 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,254.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $1,115.85 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $237.03 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $112.31 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Libtayo Clinical Publication Program | Regeneron Pharmaceuticals, Inc. | $478.43 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 77 | 93 | $88,072 | $11,641 |
| 2022 | 14 | 403 | 812 | $236,623 | $55,816 |
| 2021 | 35 | 1,558 | 86,238 | $4.3M | $862,869 |
| 2020 | 32 | 1,444 | 78,359 | $3.8M | $866,213 |
Total Patients
3,482
Total Services
165,502
Medicare Billing
$1.8M
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 40 | $34,320 | $4,136 | 12.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $31,280 | $4,118 | 13.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 16 | $15,360 | $2,345 | 15.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 14 | $7,112 | $1,042 | 14.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 130 | 243 | $68,819 | $16,412 | 23.8% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2022 | 15 | 15 | $40,790 | $10,301 | 25.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 53 | 53 | $28,215 | $6,823 | 24.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 34 | 55 | $23,045 | $6,242 | 27.1% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2022 | 11 | 11 | $21,311 | $2,838 | 13.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 41 | 54 | $10,651 | $2,716 | 25.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 16 | $9,056 | $2,445 | 27.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 19 | 24 | $15,984 | $2,326 | 14.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 12 | 13 | $2,080 | $2,080 | 100.0% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2022 | 12 | 12 | $6,382 | $1,720 | 27.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 24 | 34 | $3,678 | $858.48 | 23.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 11 | 45 | $4,590 | $561.60 | 12.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 17 | 17 | $1,802 | $471.84 | 26.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 11 | 220 | $220.00 | $20.90 | 9.5% |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 2021 | 20 | 8,012 | $1.5M | $328,484 | 22.3% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2021 | 12 | 7,200 | $976,200 | $297,905 | 30.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 58 | 315 | $50,400 | $50,400 | 100.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 79 | 355 | $230,436 | $38,581 | 16.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 190 | 390 | $84,630 | $36,009 | 42.5% |
| 58571 | Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | Facility | 2021 | 28 | 28 | $81,704 | $20,101 | 24.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 96 | 96 | $40,224 | $15,735 | 39.1% |
About Dr. Dana Chase, M.D
Dr. Dana Chase, M.D is a Gynecologic Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1396888947.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dana Chase, M.D has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $213,005 received in 2024. These payments were reported across 1,088 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($866,414).
As a Medicare-enrolled provider, Chase has provided services to 3,482 Medicare beneficiaries, totaling 165,502 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Other Specialties Gynecologic Oncology
- Location Los Angeles, CA
- Active Since 02/14/2007
- Last Updated 02/03/2023
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1396888947
Products in Payments
- LYNPARZA (Drug) $464,071
- ZEJULA (Drug) $180,615
- JEMPERLI (Biological) $149,131
- Rubraca (Drug) $59,620
- Lenvima (Drug) $59,585
- TIVDAK (Biological) $58,927
- Avastin (Biological) $36,114
- Tivdak (Drug) $30,556
- ELAHERE (Drug) $30,182
- TIVDAK (Drug) $25,774
- KEYTRUDA (Biological) $20,961
- FLOSEAL (Biological) $15,571
- Da Vinci Surgical System (Device) $12,431
- Elahere (Biological) $10,558
- LYNPARZA (Biological) $8,567
- XPOVIO (Drug) $6,085
- MD cobas Instruments and Reagents (Device) $5,971
- ENHERTU (Biological) $5,480
- Monoferric (Drug) $4,585
- SUSTOL (Drug) $4,381
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Los Angeles
Ritu Salani, Md, MD
Gynecologic Oncology — Payments: $175,767
Gynecologic Oncology $175,767
Eijean Wu, Md, Mpp, MD, MPP
Gynecologic Oncology — Payments: $13,463
Gynecologic Oncology $13,463
Dr. Michael Manuel, M.d, M.D
Gynecologic Oncology — Payments: $4,550
Gynecologic Oncology $4,550
Dr. Natsai Nyakudarika, M.d, M.D
Gynecologic Oncology — Payments: $4,096
Gynecologic Oncology $4,096
Xiaoyue Guo, Md, MD
Gynecologic Oncology — Payments: $3,983
Gynecologic Oncology $3,983
Huyen Pham, M.d, M.D
Gynecologic Oncology — Payments: $3,926
Gynecologic Oncology $3,926